AFANAT 40MG TABLET

AFANAT 40mg Tablet contains afatinib dimaleate, a second-generation EGFR tyrosine kinase inhibitor (TKI) used in the treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). It works by irreversibly blocking the EGFR signaling pathways responsible for tumor growth and progression, thereby helping to slow disease advancement.

AFANAT 40 mg Tablet is indicated for patients with advanced or metastatic NSCLC who have confirmed EGFR mutations identified through appropriate diagnostic testing. By selectively inhibiting abnormal EGFR activity, it helps limit cancer cell multiplication and supports improved disease control. This targeted therapy is administered under the supervision of a qualified oncologist to ensure safety, efficacy, and proper treatment monitoring.

AFANAT 40 mg Tablet is an important component of targeted lung cancer therapy, offering a focused treatment approach with clinically proven benefits. This anticancer medicine is manufactured in WHO-GMP-certified facilities and is suitable for hospital use, oncology supply chains, bulk procurement, and global export markets, making it a reliable product choice for EGFR-mutated NSCLC management.

Product Features

• Contains Afatinib Dimaleate 40 mg
• Second-generation EGFR tyrosine kinase inhibitor (TKI)
• Indicated for EGFR mutation-positive NSCLC
• Irreversibly inhibits EGFR signalling pathways
• Helps control tumour growth and disease progression
• Oral tablet for convenient administration
• Prescribed under the oncologist’s supervision only
• Manufactured in WHO-GMP certified facilities
• Available for bulk, wholesale & export supply

How It Helps

• Slows the growth of EGFR mutation-positive cancer cells
• Controls tumour progression and disease advancement
• Supports targeted therapy under the oncologist’s supervision
• Reduces the impact on healthy cells compared to traditional chemotherapy